Study sheds light on role of stem cells in children's brain tumor

January 11, 2010

(PhysOrg.com) -- New research from scientists at Queen Mary, University of London shows how the most common type of children's brain cancer can arise from stem cells.

Scientists know relatively little about medulloblastomas or why some cases respond better to treatments than others.

The new research, published today in , shows that medulloblastomas can grow from a type of stem cell and that these cancers are a distinct form of the disease which may require a completely different approach to treatment.

Medulloblastomas account for one in five of all children's brain tumours. They are most common in children between the ages of three and eight but they can also affect young adults.

Silvia Marino, Professor of at Queen Mary, University of London, led the study. She said: "This type of can pose a great challenge to doctors. In some children, treatment works well but in others the cancer is aggressive and far harder to treat.

"As scientists we've been trying to understand how these cancers which look the same can behave so differently.

"This study is a major advance for us because it shows for the first time that some of these tumours develop from endogenous .

"This is important for two reasons. First, it could help us to tell which cancers will respond well to treatment and which will need a more aggressive therapy. Second, this new understanding could help us to find much-needed new drugs for the disease."

Previous research has shown that human brains contain a small number of stem cells - called - which enable the brain to repair itself to some degree. Professor Marino and her team studied equivalent cells taken from mouse brains.

They found that two particular called Rb and p53, which are already known to play a role in cancer, could malfunction in these cells and allow the cells to grow uncontrollably. They also found that in mice, these cells turned into medulloblastomas.

The researchers then looked more closely at the genetic makeup of these tumours and found a particular pattern which they compared with tumours taken from patients with medulloblastomas. They found that patients whose tumours also had this genetic pattern were those with the worst survival chances.

The researchers believe that their findings are a crucial first step in understanding the most aggressive form of this disease. They can now begin to look for new ways to tackle the disease in a more effective and possibly less toxic way.

More information: Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas, Sutter R, et al, Oncogene, 2010, 1-12

Related Stories

Recommended for you

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

Computer program finds new uses for old drugs

November 16, 2017
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, ...

Pharmacoscopy improves therapy for relapsed blood cancer in a first clinical trial

November 16, 2017
Researchers at CeMM and the Medical University of Vienna presented a preliminary report in The Lancet Hematology on the clinical impact of an integrated ex vivo approach called pharmacoscopy. The procedures measure single-cell ...

Wider sampling of tumor tissues may guide drug choice, improve outcomes

November 15, 2017
A new study focused on describing genetic variations within a primary tumor, differences between the primary and a metastatic branch of that tumor, and additional diversity found in tumor DNA in the blood stream could help ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.